Instil Bio (TIL) Profit After Tax (2020 - 2026)
Instil Bio (TIL) posted quarterly Profit After Tax of -$4.2 million for Q1 2026, up 85.39% year-over-year from -$2.2 million in Q1 2025, and up 49.3% quarter-over-quarter from -$8.2 million in Q4 2025.
Instil Bio (TIL) Profit After Tax (2020 - 2026) Analysis & Trends
Instil Bio's Profit After Tax history runs 7 years deep, the most recent figure standing at -$4.2 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 85.39% year-over-year to -$4.2 million; the TTM figure through Mar 2026 stood at -$47.1 million (up 39.56% YoY), while the FY2025 annual figure was -$71.4 million, up 3.73% from the prior year.
- Profit After Tax for Q1 2026 stood at -$4.2 million, up from -$8.2 million in the prior quarter.
- The five-year high for Profit After Tax was -$4.2 million in Q1 2026, with the low at -$67.2 million in Q3 2023.
- The 5-year median for Profit After Tax is -$22.9 million (2024), against an average of -$31.1 million.
- The sharpest annual moves came in 2022 and 2026: Profit After Tax tumbled 133.99% in 2022, then jumped 85.39% in 2026.
- Instil Bio's Profit After Tax stood at -$54.2 million in 2022, then surged by 76.44% to -$12.8 million in 2023, then climbed by 8.27% to -$11.7 million in 2024, then jumped by 30.13% to -$8.2 million in 2025, then jumped by 49.3% to -$4.2 million in 2026.
- Business Quant data shows TIL's Profit After Tax at -$4.2 million in Q1 2026, -$8.2 million in Q4 2025, and -$13.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | -4.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.35 Mn |
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | -8.19 Mn |
| Sep 30, 2025 | -13.39 Mn |
| Jun 30, 2025 | -21.39 Mn |
| Mar 31, 2025 | -28.42 Mn |
| Dec 31, 2024 | -11.72 Mn |
| Sep 30, 2024 | -22.91 Mn |
| Jun 30, 2024 | -14.92 Mn |
| Mar 31, 2024 | -24.30 Mn |
| Dec 31, 2023 | -12.78 Mn |
| Sep 30, 2023 | -67.16 Mn |
| Jun 30, 2023 | -18.66 Mn |
| Mar 31, 2023 | -57.07 Mn |
| Dec 31, 2022 | -54.25 Mn |
| Sep 30, 2022 | -56.22 Mn |
| Jun 30, 2022 | -58.99 Mn |
| Mar 31, 2022 | -54.12 Mn |
| Dec 31, 2021 | -55.33 Mn |
| Sep 30, 2021 | -43.01 Mn |